SEC EDGARSEP 171 min read$MDT

KIIL HARRY SKIP sold $139K of MDT

KIIL HARRY SKIP (EVP & President Cardiovascular) sold 1,483 shares of Medtronic plc (MDT) at $93.65 ($0.14M total) on 2026-09-16.

Original reporting

SEC EDGAR · KIIL HARRY SKIP

Published Sep 17, 2026, 8:17 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 17, 2026, 8:28 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$MDT

Neutral

high confidence

Mentioned

$MDT

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$MDTNeutralLow

Why it matters

The transaction is a routine insider sale with limited market relevance.

Market read

Low relevance; small insider sell unlikely to affect stock price.

What to watch

Holding after sale remains 42,186 shares, indicating continued confidence.

Relevance 4/10Novelty 4/10Timing: post‑market 2026‑09‑16

Background

Form 4 filings disclose insider transactions; traders monitor for material buys/sells.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$MDTNeutralHigh confidence

Context

EVP Harry Skip sold 1,483 Medtronic shares for $138,883 on 2026-09-16.

Expected impact

minimal impact, likely negligible price change

Evidence & confidence

Sale size is small relative to market cap; insider is not a major holder.

Market effects

Sector

None; Medtronic operates in medical devices with no sector‑wide impact from this sale.

Regional

None; US‑listed health‑care sector unchanged.

Global

None

Counterpoint

What could challenge this read

Insider sale could signal personal liquidity need, but size is too small to infer company outlook.

Key entities

Officer
Harry Skip
EVP & President Cardiovascular at Medtronic
Company
Medtronic plc
Medical device manufacturer (ticker MDT)

Read at source ← All news

OCT 23

$MDTMed

Diabetes Dialogue: MiniMed Vivera Data and Twiist Type 2 Clearance

Medtronic's MiniMed Vivera algorithm showed promise in managing type 1 diabetes without meal announcements, with participants maintaining glycemic targets. The twiist AID system from Sequel Med Tech received FDA clearance for type 2 diabetes, showing improved HbA1c and time-in-range in trials. Both systems aim to reduce user input in automated insulin delivery.

hcplive.com2 min

OCT 23

$MDTMed

Medtronic reports real-world findings for cardiac ablation systems

Medtronic reported positive real-world registry findings for its cardiac ablation technologies, presented at the APHRS 2026 meeting. The PulseSelect PFA system showed a 100% success rate in AFib patients with a 0.09% complication rate. The Affera system with Sphere-9 catheter had a 1.1% major complication rate in AFib patients and an 87% success rate in VT patients. Medtronic's vice-president expressed confidence in the safety and performance of these technologies.

finance.yahoo.com2 min

OCT 22

$JNJMedAI 9/10

J&J, Medtronic present pulsed field ablation data from global real-world use

J&J and Medtronic presented data on their pulsed field ablation platforms at the Asia Pacific Heart Rhythm Society meeting. J&J's Varipulse Pro showed 100% procedural success in 225 European patients with no major complications. Medtronic's PulseSelect had a 100% success rate and 0.09% major complication rate in 1,160 global patients. Both companies also shared data on upcoming systems and catheters.

massdevice.com2 min

OCT 22

$MDTMedAI 8/10

Medtronic Reports Positive Real-World Data For Cardiac Ablation Systems

Medtronic (MDT) presented positive real-world data for its cardiac ablation systems at the APHRS 2026 meeting. The Sphere-9 catheter and PulseSelect PFA system showed low complication rates and high success rates in treating heart rhythm disorders. MDT stock closed at $93.03, up 0.25% in pre-market trading.

rttnews.com2 min

OCT 20

MedAI 8/10

Medtronic’s next-gen pacemaker portfolio secures CE mark

Medtronic's Vitalis portfolio of next-gen pacemakers, designed for conduction system pacing (CSP) therapy, received a CE mark. The five pacemakers include advanced features like AdaptivCSP for heart synchrony. Medtronic claims this offers a more physiologic pacing option. GlobalData reports Medtronic leads the US pacemaker market with 58.7% share in 2025, with the global market growing at a 4.9% CAGR.

medicaldevice-network.com2 min

OCT 19

$MDTHigh

Medtronic nets CE Mark for Vitalis family of conduction system pacemakers

Medtronic (MDT) received CE Mark approval for its Vitalis family of pacemakers, designed for conduction system pacing. The portfolio includes five devices targeting various patient needs, such as the ReSyncra CSP for cardiac resynchronization therapy. The devices aim to improve heart synchronization by targeting conductive tissues, offering personalized therapy and remote monitoring. According to Medtronic, the portfolio builds on its history in cardiac electrophysiology therapies.